7 completed, 2 withdrawn. 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
Follow NBI 77860: new trials by email Literature Review of NBI 77860 trials Research Report on NBI 77860
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia NBI-77860 - Congenital Adrenal Hyperplasia | Phase 1 | Withdrawn | Neurocrine Biosciences | 2015-02-01 | 2015-06-11 | |
| Analyzing Female Trauma Exposed Responses to a Medication GSK561679, Placebo - Stress Disorders, Post-traumatic | Phase 2 | Completed | VA Office of Research and Development | 128 | 2010-01-01 | 2021-06-25 |
| CRF1 Antagonist GSK561679 in Alcoholism GSK561679, Placebo - Alcohol Dependence | Phase 2 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 44 | 2010-01-01 | 2016-11-07 |
| Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder GSK561679, Placebo - Stress Disorders, Post-Traumatic | Phase 2 | Completed | Emory University | 267 | 2009-12-01 | 2017-03-07 |
| A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder GSK561679, Placebo - Depressive Disorder, Major | Phase 2 | Completed | GlaxoSmithKline | 150 | 2008-10-02 | 2017-11-17 |
| A Study to Examine the Absorption of GSK561679 in Healthy Male Volunteers GSK561679 tablet or solution - Healthy Subjects | Phase 1 | Completed | GlaxoSmithKline | 12 | 2007-10-01 | 2010-10-19 |
| A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679 GW876008 and GSK561679 - Irritable Bowel Syndrome | Phase 2 | Withdrawn | GlaxoSmithKline | 2007-08-01 | 2015-03-02 | |
| A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder GSK561679 tablet, GW876008 tablet, alprazolam - Social Phobia | Phase 1 | Completed | GlaxoSmithKline | 35 | 2007-03-27 | 2017-08-04 |
| To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones. metyrapone, alprazolam, placebo - Depressive Disorder and Anxiety Disorders | Phase 1 | Completed | GlaxoSmithKline | 20 | 2006-10-06 | 2017-09-11 |
Anxiety Disorders (4) · Stress Disorders, Post-Traumatic (2) · Adrenal Gland Diseases (1) · Adrenal Hyperplasia, Congenital (1) · Adrenocortical Hyperfunction (1) · Adrenogenital Syndrome (1) · Alcoholism (1) · Behavior, Addictive (1) · Congenital Abnormalities (1) · Congenital adrenal hyperplasia due to 21 hydroxylase deficiency (1) · Depression (1) · Depressive Disorder (1) · Depressive Disorder, Major (1) · Disorders of Sex Development (1) · Endocrine System Diseases (1)
GlaxoSmithKline (5) · Emory University (1) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · Neurocrine Biosciences (1) · VA Office of Research and Development (1)
United States (6) · Spain (1) · United Kingdom (1)
Boadie Dunlop, MD (1) · Lorenzo Leggio, M.D. (1) · Thomas C. Neylan, MD (1)